Tianyin Biotech Secures Over RMB 10 Million in Funding; Brain-Computer Interface Industrial Cluster Launches in Shanghai Hongqiao

1. All coordinated regions in China are required to implement real-time settlement by the end of this year.

Recently, the National Healthcare Security Administration issued the "Notice on Comprehensively Promoting the Expansion and Quality Improvement of Immediate Settlement Reform for Medical Insurance Funds," requiring that by the end of 2025, all coordinating regions in China must implement immediate settlement. By the end of 2026, the funds from immediate settlement should account for more than 80% of the local medical insurance fund’s monthly settlement funds, and by the end of 2026, over 80% of designated medical institutions should have immediate settlement services available. The notice proposes strengthening the construction of the immediate settlement mechanism, standardizing the fund disbursement mechanism, reinforcing the review and control mechanism, improving the evaluation and supervision mechanism, and establishing a risk warning mechanism. Regarding the standardization of fund disbursement, the notice suggests that provincial healthcare security departments guide coordinating regions’ designated medical and pharmaceutical institutions to, in principle, submit medical expense claims before the 10th day of the following month. (China Workers' Network)

2. Brain-Computer Interface Future Industrial Cluster Lands in Shanghai Hongqiao

Recently, according to the report by *The Science and Technology Innovation Board Daily*, the future industrial cluster of brain-computer interface has been established in Shanghai Hongqiao. Both the Shanghai municipal government, Minhang District, and Hongqiao International Central Business District are promoting the construction of this cluster through municipal and district-level policy resources. The report also mentioned three development paths for the cluster: First, building an industrial cluster with “one core, one circle, one network.” Second, creating a source of technological innovation by relying on universities and key laboratories to drive breakthroughs in fields such as brain-computer interface, neuroscience, and underlying algorithms. Third, increasing policy support by systematically constructing a “industry-university-research-application-capital” integrated ecosystem covering the entire process from “innovative research and development - clinical transformation - incubation acceleration.” (IT Home)

3. Tianjin Explores the Establishment of a Permanent Residence-Based Elderly Care Service Supply Mechanism

Recently, the Tianjin Municipal People's Government released the Implementation Opinions on Deepening the Reform and Development of Elderly Care Services. It proposed to further promote the coordinated development of elderly care services in the Beijing-Tianjin-Hebei region. In accordance with the principles of government guidance, market operation, cooperative construction, and equal standards, the city’s high-quality elderly care resources will be extended to Beijing and Hebei. Efforts will explore establishing a mechanism for providing elderly care services based on place of residence and improve the cross-regional settlement system for elderly care services among the three regions. The initiative aims to enhance the coordination mechanism for elderly care services in the Beijing-Tianjin-Hebei region, continuously deepen interconnectivity in medical insurance, social security, and elderly care, with a focus on promoting synergy in policies, projects, talent, medical-care integration, regional cooperation, and industry alignment. It also seeks to advance the alignment and mutual recognition of policies, standards, and data related to the elderly care services industry across the three regions, achieving open sharing of elderly care resources and information. The role of social organizations in the field of elderly care services will be leveraged to facilitate the connection of projects and resources in the three regions, exploring new pathways for cooperation in elderly care services. (Jinshi Data)

4. Hangzhou "Brain Science Innovation Demonstration Center" Inaugurated

Recently, the "Brain-Computer Science Innovation Demonstration Center" located in the China (Hangzhou) Artificial Intelligence Town officially opened. As an important window to showcase the achievements of the brain-computer interface industry, the exhibition hall was built by Hangzhou Future Sci-Tech City Innovation Development Co., Ltd., and relies on BrainCo to create a comprehensive presentation of the brain-computer interface from scientific exploration to industrial implementation. Inside the "Hangzhou Future Sci-Tech City Brain-Computer Industry Panorama Exhibition Space," the exhibits focus on the global brain-computer industry map, highlighting the key directions of the future industry strategic layout at the national, provincial, and municipal levels. Hangzhou is focused on building a “Neuromorphic Intelligence Future Industry Pilot Zone” as its core, establishing an integrated innovation ecosystem for basic research, technology transfer, and industrial application, attracting several industry-leading companies including BrainCo. (Qianlong Network)

5. Chinese-produced IVD Sub-sector Leader Enters High-end Medical Imaging

Recently, Awei Technology announced that it plans to invest 10 million yuan of its own funds to increase the capital of Hunan Luying Technology Co., Ltd. After the capital increase is completed, Awei Technology will hold 9.07% of Luying Technology's shares, becoming the fifth largest shareholder and the only industrial investor, officially entering the high-end nuclear medicine imaging equipment track. The announcement shows that Luying Technology is a technology achievement transformation project of the team led by Vice President and Professor Jiang Jianhui of Hunan University. The project is committed to the development of high-resolution Single Photon Emission Computed Tomography (SPECT) and its core components, aiming to provide precise, safe, economical, and convenient molecular imaging diagnostic technology solutions, promoting the domestic substitution and upgrading of high-end nuclear medicine imaging equipment. (Medical Device Business Review)

6. Medical Device Company Vascular Flow's Helical Graft Receives FDA Approval for Market Launch

Recently, Vascular Flow announced that its spiral-shaped artificial blood vessel, SLF AV, has received FDA approval for marketing. It is the first FDA-approved spiral-shaped artificial blood vessel, designed for arteriovenous fistula creation. Globally, over 2 million patients with kidney disease rely on hemodialysis each year. The arteriovenous fistula serves as a "lifeline" for dialysis patients, but it has a high postoperative failure rate, with early dysfunction occurring in about 40% of cases. Failures are mostly caused by turbulent flow-induced thrombosis, while later dysfunction is related to venous hypertension and vascular wall tension. Avoiding or delaying intimal hyperplasia is key to extending the lifespan of arteriovenous fistulas, yet existing solutions fail to meet clinical needs. SLF AV is made from expanded polytetrafluoroethylene (ePTFE) and its unique feature lies in the spiral design at the venous end, which remodels blood flow into a spiral laminar pattern, reduces turbulent energy, brings blood flow closer to physiological conditions, significantly decreases intravascular turbulence, and lowers pressure and stress on the vessel walls. (MedTF)

7. R&D Design Services Accelerate the Clinical Transformation of Medical Research Achievements

The research and development of medical devices is a complex and rigorous process, involving multiple aspects such as technology, regulations, and clinical practices. OrthoChain has a 20,000-square-meter science and innovation center and has established a Medical Device Research Institute dedicated to the clinical transformation of medical research achievements. It boasts a high-level, international, multidisciplinary professional team proficient in the entire process of R&D, regulations, clinical trials, registration, and production, capable of developing and producing various complex innovative products. With extensive project experience and industry resources, OrthoChain has built a standardized, regulated, and digitalized full-process service system. It provides one-stop services ranging from initial market research, product concept generation, product design and development to prototype production and testing. To date, OrthoChain has had over 200 projects enter the review stage, with more than 100 projects currently under development, achieving a 100% success rate in transformation. (Compiled by OrthoChain)

8. Tianyin Bio Completes Financing of Over RMB 10 Million

Recently, Shanghai Tianyin Biotechnology Co., Ltd. announced the completion of a multi-million yuan financing round, led by Shanghai Industrial Intellectual Property Fund under Shanghai Science and Technology Innovation Group. This round of financing will be used to advance technology research and development, product implementation, market expansion, and medical insurance access. Founded in 2016 in Minhang District, Shanghai, Tianyin Biotech is a commercialization enterprise of scientific research achievements from Shanghai Jiao Tong University, focusing on objective detection and intervention for mental and psychological disorders. Tianyin Biotech has developed an objective biological detection technology, the Nicotinic Skin Reaction (NSR) test, which can guide clinical interventions. It enables early screening, precise evaluation, and personalized treatment guidance for mental health conditions such as depression. Based on this original breakthrough, Tianyin Biotech has built a complete product system covering the entire medical process of "risk screening-medical testing-personalized intervention-health management." (Investment Community)